Cognivue risk score rapidly and effectively measures and monitors cognitive health.

Clinical cognitive testing solution

Cognivue was designed to measure a patient’s early clinical risk score  objectively, quantitatively and reliably. It allows you to preserve a patients’ cognitive health by establishing a baseline cognitive risk score that can be monitored over time. It is the first cognitive test cleared by the FDA for patients over the age of 55. It is based on years of research focusing on early detection of late-life cognitive decline (LLCD) and dementia. Here is how we are working with patients and health care providers to leverage its benefits.



For Primary Care Providers

No referrals are necessary. Cognivue is a rapid, office-based solution for routine cognitive function monitoring .

  • 10 sub-tests in 10 minutes
  • 4 key domains of the brain
  • Self-administered
  • Test is reimbursable
Patients Family

For Patients and Family

Cognivue enables cognitive function testing, which allows for early identification and risk stratification. It can detect early signs cognitive decline, for patients in all healthcare settings—working with their personal physician, who knows them best.

  • Accessible testing across time and location
  • Immediate results
  • Single, quantitative cognitive function risk score

For Integrated Delivery Networks (IDNs) and Payors

By Establishing an early baseline risk score, enabling early detection that allows for risk stratification for early mitigation and intervention and more effective treatment clinical outcomes, such as:

  • Treating reversible dementia
  • Managing co-morbidities
  • Avoiding complications, polypharmacy, and procedures

For the Industry

Cognivue provides rapid, standardized CRO cognitive function testing of new molecules.

  • CogniWheel™ global patient interface
  • Cloud-based results, storage, and analytics
  • Primary Care Physician (PCP) engagement in testing and monitoring of new treatments

Early and accurate diagnosis leads to better disease management, patient outcomes and improved quality of life. It also can lower state and patient costs through an orderly plan for care, rather than one filled with crisis, frequent hospital visits and unanticipated expenses. Alzheimer’s can be a cruel disease. While there is yet no cure, early diagnosis and disease management can help ease the burden on patients, their families and the state budget. We urge our lawmakers to support this reasonable budget allocation.

Bruce L. Miller, professor of neurology at the University of California, San Francisco, and director of the UCSF dementia center.


Cognivue has been a great addition!!!! Far better than the MMSE...I say it is a cognitive CBC or EKG and patients are educated in a way we couldn't do before...and so am I!

Dr. C. Stringer, CNY Internists PC


Sign-up to schedule a Cognivue demo!

Click Here